荃信生物－Ｂ(02509)与罗氏达成QX031N的全球独家许可协议

Core Viewpoint - The company, Qianxin Biotechnology-B (02509), has entered into a global exclusive collaboration and licensing agreement with F. Hoffmann-La Roche Ltd, granting Roche exclusive rights to develop, manufacture, and commercialize the product QX031N [1] Financial Summary - The company will receive a one-time, non-refundable, and non-deductible upfront payment of $75 million [1] - The company is eligible for up to $995 million in milestone payments related to product development, regulatory approval, and commercialization [1] - Additionally, the company may receive tiered royalties on future product sales [1]